A peptide fragment from the human COX3 protein disrupts association of Mycobacterium tuberculosisvirulence proteins ESAT-6 and CFP10, inhibits mycobacterial growth and mounts protective immune response
- Sachin Kumar Samuchiwal†1,
- Sultan Tousif†2, 3, 4,
- Dhiraj Kumar Singh2,
- Arun Kumar2,
- Anamika Ghosh1,
- Kuhulika Bhalla1,
- Prem Prakash1,
- Sushil Kumar1,
- Maitree Bhattacharyya3,
- Prashini Moodley4,
- Gobardhan Das4Email author and
- Anand Ranganathan1Email author
© Samuchiwal et al.; licensee BioMed Central Ltd. 2014
Received: 6 February 2014
Accepted: 25 June 2014
Published: 1 July 2014
Tuberculosis (TB) is one of the most prevalent infectious diseases affecting millions worldwide. The currently available anti-TB drugs and vaccines have proved insufficient to contain this scourge, necessitating an urgent need for identification of novel drug targets and therapeutic strategies. The disruption of crucial protein-protein interactions, especially those that are responsible for virulence in Mycobacterium tuberculosis – for example the ESAT-6:CFP10 complex – are a worthy pursuit in this direction.
We therefore sought to improvise a method to attenuate M. tuberculosis while retaining the latter’s antigenic properties. We screened peptide libraries for potent ESAT-6 binders capable of dissociating CFP10 from ESAT-6. We assessed the disruption by a peptide named HCL2, of the ESAT-6:CFP10 complex and studied its effects on mycobacterial survival and virulence.
We found that HCL2, derived from the human cytochrome c oxidase subunit 3 (COX3) protein, disrupts ESAT-6:CFP10 complex, binds ESAT-6 potently, disintegrates bacterial cell wall and inhibits extracellular as well as intracellular mycobacterial growth. In addition, an HCL2 expressing M. tuberculosis strain induces both Th1 and Th17 host protective responses.
Disruption of ESAT-6:CFP10 association could, therefore, be an alternate method for attenuating M. tuberculosis, and a possible route towards future vaccine generation.
KeywordsTuberculosis Human COX3 ESAT-6 CFP10 Protein-protein interactions Th1 Th17
Tuberculosis (TB) remains the leading cause of infectious disease-related deaths worldwide. There are an estimated 8.5-9.2 million cases and 1.2-1.5 million deaths caused by Mycobacterium tuberculosis (M.tb) each year . One-third of the global population is infected with the latent form of TB, a scenario translating into an enormous reservoir for a future pandemic. BCG, the only available vaccine, provides significant protection against disseminated and tubercular meningitis, but has very little or no efficacy against adult pulmonary TB . We have earlier shown that an optimum host protection against TB requires both Th1 and Th17 responses . BCG induces Th1 response, but fails to induce Th17 response in the lung, a factor mostly responsible for the inferior efficacy of BCG [3, 4]. Considerable efforts have been made to generate recombinant BCG but with little headway [5, 6]. On the other hand, the currently available anti-TB chemotherapy, DOTS, is lengthy, consists of multiple antibiotics that cause severe hepatotoxicity and is effective in only 50% of MDR-TB cases [7, 8]. Therefore, identification of novel therapeutic strategies is urgently needed.
A promising approach can be the targeting of important protein-protein interactions within the pathogen, with an emphasis on those proteins that are the source of mycobacterial virulence. As of now, there exist no peptides or small molecules that specifically target bacterial virulence factors. Such moieties can conveniently be used along with conventional drugs to improve TB chemotherapy and in combating multi-drug resistance . Quite often virulence is dependent on protein-protein interactions, an area that is as yet unexplored for the development of advanced therapeutics. Recently, it has been shown that ESAT-6, a protein derived from the region of difference (RD-1), plays a critical role in mounting Th17 responses in the lung [3, 4]. As stated earlier, we showed that the vaccine strain of BCG lacks the RD-1 region and is therefore unable to generate Th17 responses. Similarly, the RD-1 mutant of H37Rv also fails to induce Th17 responses . Although RD-1 recombinant BCG generates both Th1 and Th17 responses, this strain is unsuitable as a vaccine because RD-1 addition makes BCG virulent . It was, therefore, our aim to elucidate the role of interaction between RD-1 components and their potential therapeutic interventions.
In M.tb, ESAT-6 and CFP10 proteins are encoded by the RD1 region (9.5 kb in length comprising 9 genes – part of ESX1 secretion system), and secreted as a tight 1:1 heterodimer with a dissociation constant of 1.1 × 10-8 M [11, 12]. It is well known that the ESAT-6:CFP10 complex plays pivotal role in the pathogenesis of TB. Indeed, deletion of ESAT-6 or RD1 locus attenuates M.tb and dramatically reduces vaccine efficacy of the attenuated mutants [3, 13]. The many crucial roles of ESAT-6 include membrane lytic activity due to its helix-turn-helix structure and hydrophobic nature that helps mycobacteria escape from phagolysosome and spread , as well as macrophagial aggregation and granuloma formation, leading to intercellular bacterial dissemination . It is becoming increasingly clear that ESAT-6 is decisive for the virulence, pathogenesis, and survival of M.tb.
Therefore, to understand whether in vivo disruption of a protein complex that involves ESAT-6 as a primary component has an effect on the pathogenesis of M. tuberculosis, we screened peptides that bind to ESAT-6 with potent affinity and are capable of dissociating CFP10 from ESAT-6. We report here the strong binding capability of a peptide named HCL2 (amino acid sequence: ESTYQGH-HTPPVQKGLRYGIILFITSEVFFFAGFF*), a fragment from human mitochondrial protein COX3, with ESAT-6. We assessed the disruption by HCL2 of the ESAT-6:CFP10 complex by employing a Bacterial Three-Hybrid system recently developed in our laboratory  and report a direct correlation in HCL2 expression and ESAT-6:CFP10 disruption. We determined the effects of exogenous and endogenous HCL2 on the growth of M.tb and observed significant bacteriocidal effects and changes in cellular and colony morphology. Furthermore, we report the generation of an HCL2-expressing H37Rv strain, infection by which induces IL-12 as well as IL-6 production in macrophages, which are the polarizing cytokines for Th1 and Th17 differentiations respectively. Therefore the present study extends our earlier studies regarding BCG and Th17 responses , and establishes as a proof of concept, the development of an alternative strain for therapeutic intervention. In addition, HCL2 could also serve as a template for designing new and improved peptide-based therapeutics against TB.
Antibodies and reagents
We used rabbit anti-ESAT-6 antibody (Abcam, Cambridge, MA), mouse anti-His6X antibody (Sigma-Aldrich, St. Louis MA), anti-FLAG antibody (Sigma-Aldrich, St. Louis MA), HRP conjugated anti-mouse IgG (Bio-rad, Hercules, CA), anti-rabbit FITC conjugated secondary antibody (Jackson-ImmunoResearch, West Grove, PA) and anti-mouse Texas Red secondary antibody (Jackson-ImmunoResearch, West Grove, PA) for in vitro studies. For in vivo studies, anti-CD4 (clone: GK1.5)-FITC, -PerCP-Cy5 or -APC, anti-CD8 (clone: 53–6.7)-FITC, -PerCP-Cy5 or -APC, anti-CD44 (clone: IM7)-APC, anti-Brdu (clone: Bu20a)-PE, anti-CD11b (clone: M1/70)-APC, anti-CD11c (clone: N418)-APC, 7AAD, anti-IFN-γ (clone: XMG1.2)-APC, anti-IL-17 (clone: TC11-18H10.1)-PE, anti-IL-4 (clone: 11B11)-PE, anti-IL-6 (clone: MPS-20 F3)-PE, anti-IL-12 (clone: C15.6)-PE, anti-IL-22 (clone: Poly5164)-PE, anti-IL-10 (clone: JES5-16E3)-PE, anti-IL-9 (clone: MH9A4)-PE, anti-TNF-α (clone: MP6-XT22)-PE, (all from Biolegend, USA) and anti-CD69 (clone: H1.2 F3)-PE (from eBiosciences, USA) were used.
BALB/c female mice at 6–8 weeks of age were used throughout this study, following institutional ethical committee guidelines. All animal experiments were conducted in accordance with guidelines approved by the Institutional Animals Ethics Committee of ICGEB, New Delhi, India and Department of Biotechnology (DBT), Government of India. Mice were housed under barrier conditions in a Biosafety Level III laboratory.
Bacterial two-hybrid studies
Bacteriomatch™ system was used as described earlier [16, 17]. Two colonies each from HCL2pTRGnn + ESAT-6pBTnn, positive and negative, were grown in cultures and patched on X-gal indicator plate. Interactions were validated by liquid β-Galactosidase assay and compared with well-established mycobacterial interaction between ESAT-6 and CFP10 (ESAT-6pBTnn + CFP10pTRGnn).
In vitroFar-Western Dot Blot analysis
For Far-Western Dot Blot assay, ESAT-6-FLAG was purified by ion-exchange chromatography. Briefly, E. coli BL21 (DE3) cells harboring flagesat6pET28a were subjected to IPTG induction and cells were harvested, lysed in denaturing condition. Clear supernatant was allowed to bind on DEAE-sepharose (Amersham) followed by washing with lysis buffer and the resin bound proteins were eluted using a gradient of NaCl from 0 M to 1 M, prepared in lysis buffer. Purified protein was refolded by sequential dialysis against PBS with decreasing concentration of urea. The interaction between ESAT-6-FLAG and HCL2-His6X (commercially synthesized from GenScript, Hong Kong) was determined using a protocol reported previously . An unrelated protein ED3-His6X (sequence given in Additional file 1: Figure S1) was used as a negative control. CFP10-His6X and ESAT-6-FLAG were used as positive controls.
Cloning of HCL2 in pMTSA vector
The ORF encoding HCL2 peptide was amplified from original lung cDNA library clone using 5’-AAGGATCCTACGTAAGAATTCGGCACGAG-3’ and 5’-AAGGATCCTACGTAGAAAA ATCCTGCGAAGAAAA-3’ as forward and reverse primers respectively. The gene was cloned in a SnaBI site in an arabinose-inducible three-hybrid vector as previously described . Expression of HCL2-His6X was analyzed on Tricine-SDS PAGE and Western Blotting was done using Anti-His6X antibodies.
Bacterial Three-Hybrid and arabinose gradient liquid β-Galactosidase assay
Bacterial Three-Hybrid studies were carried out as described earlier . To study the correlation between disruption of the ESAT-6:CFP10 interaction and in vivo expression levels of HCL2, an Arabinose gradient liquid β-Galactosidase assay was performed. The experiment was carried out in triplicates by varying L-arabinose concentration ranging from 0 to 1%. Western Blotting was done with increasing concentration of L-arabinose (0-1%), to show the gradual increase in HCL2-His6X induction corresponding to decrease in β-Galactosidase activity.
HCL2 cloning in a mycobacterial shuttle vector
The ORF expressing HCL2 peptide was cloned in mycobacterial constitutive expression vector pVV16 and pVVGFPHis6X and used to electroporate H37Rv electro-competent cells, as described earlier .
Effect of HCL2 on M. tuberculosisgrowth
We examined the effects of HCL2 peptide on M.tb growth by using two methods. First, by electroporating HCL2pVV16 (H37Rv/HCL2; strain expressing HCL2-His6X) and secondly by adding HCL2-His6X peptide to the culture exogenously at a final concentration of 15 μg/ml (H37Rv + HCL2). HCL2 was cloned in mycobacterial constitutive expression vector pVV16 as described earlier . Cultures were inoculated in triplicates each for H37Rv/HCL2, H37Rv + HCL2, H37Rv/pVV16 (strain having only plasmid control), ΔRD1, H37Rv/GFP, H37Rv + DL1 and H37Rv and assessed spectrophotometrically for 18 days at 630 nm. H37Rv was added with equivalent amount of Milli-Q water used to dissolve the peptide HCL2-His6X. A higher concentration of HCL2-His6X was not used due to precipitation of the peptide at concentrations > 15 μg/ml. Strain lacking RD1 region (ΔRD1; kind gift of Prof. David R. Sherman), H37Rv expressing GFP (H37Rv/GFP), and addition of an unrelated peptide (sequence given in Additional file 1: Figure S1) DL1 (H37Rv + DL1) were used as controls. Another ESAT6 binding peptide, SL3, from our previous studies  was also analyzed for its effects on mycobacterial growth during this study (unpublished results).
Effect of HCL2 on cellular and colony morphology
Electron microscopy was carried out to examine the effect of endogenous or exogenous HCL2 on cellular morphology of M.tb. H37Rv/HCL2, H37Rv + HCL2, H37Rv, ΔRD1 and H37Rv/pVV16 cells were fixed by treating with 2% paraformaldehyde solution and adsorbed on a 300 mesh copper grid and air dried. Samples were stained with 1% uranyl acetate followed by photography using a FEI Tecnai 12 Electron Microscope. H37Rv, H37Rv/pVV16 and ΔRD1 strains were used as controls. In addition, colony morphology of H37Rv/HCL2 strain was observed on 7H11 plates and colony texture was compared with H37Rv.
Infection of THP-1 cells by M. tuberculosisin presence of HCL2 peptide
Approximately 12,000/well phorbol-12-myristate-13-acetate (Sigma, USA) activated THP-1 cells in a 96 well flat bottom tissue culture plate were infected with M.tb H37Rv/HCL2 at an MOI of 1:10 using a protocol described previously . Cells were harvested, lysed and plated on 7H11 agar at 0, 24, 48 and 72 hours and CFU counts determined. For effects of exogenous HCL2-His6X (H37Rv + HCL2), peptide was added to RPMI media at a final concentration of 15 μg/ml and this media was added to H37Rv infected tissue-culture plates at 0 hours and changed after every 24 hours till 72 hours. H37Rv, H37Rv/GFP, H37Rv + DL1 and ΔRD1 were used as control strains to infect THP-1 cells. In this experiment, SL3 peptide was also analyzed for its effects on intracellular survival (unpublished results).
Mice infection with H37Rv/HCL2, CFU counts and immunology
BALB/c mice were infected with ~150 CFU of H37Rv and H37Rv/HCL2 using an aerosol chamber. Mice were sacrificed at different time points and cytokine profile and T lymphocytes proliferation were assessed as described earlier . For CFU counts lung and spleen were harvested at different time points and processed as described previously .
All experiments were repeated thrice and in triplicates. Mean values were calculated with standard deviation (STDEV) unless stated otherwise. For all statistical analyses Student's T-test was performed to compare two groups; p < 0.05 was considered significant.
HCL2 interacts with ESAT-6 in vitro
HCL2 can disrupt the ESAT-6:CFP10 heterodimeric complex
Bacterial three-hybrid studies demonstrated that presence of HCL2 peptide in a cell expressing ESAT-6 and CFP10 changes the colony color from blue to white, thereby disrupting ESAT-6:CFP10 interaction (Figure 1D). An arabinose gradient liquid β-Galactosidase assay exhibited a concomitant decrease in β-Galactosidase activity with a proportionate HCL2 expression, observed by Western blotting with Anti-His6X antibodies (Figure 1E), confirming a robust expression of HCL2-His6X peptide in three-hybrid experiments.
HCL2 inhibits mycobacterial growth in axenic cultures
HCL2 affects cellular and colony morphology
HCL2 inhibits mycobacterial growth in THP-1 cell line
It is clear that expression of HCL2 in M. tuberculosis renders slow growth in liquid cultures. This however does not reflect the status of virulence. Indeed, some of the drug resistant and mutant strains grow slower than the parent H37Rv. In an intracellular survival experiment, we observed that uptake of both H37Rv and H37Rv/HCL2 was similar by THP-1 cells. However, a drastic reduction of bacterial load after 72 hours was noticed in the mutant HCL2 strain. The control strains such as H37Rv/pVV16, H37Rv/GFP and ΔRD1 continued to grow as reported previously (Figure 3C). Similar reductions in CFU counts were observed when HCL2 was added exogenously over infected THP-1 cells (Figure 3C). Any possible cytotoxic effects of HCL2 on THP-1 cells were studied by MTT assay at 0, 24, 48 and 72 hours after addition of 15 μg/ml HCL2 peptide. No cytotoxicity was observed (data not shown). These observations indicated to us that HCL2 potentially disrupts virulence. It is important to notice here that the inhibition of intracellular growth is similar to that of the avirulent ΔRD1 mutant, suggesting that disruption of ESAT-6:CFP10 leads to a similar attenuation outcome.
M. tuberculosis H37Rv/HCL2mounts host protective immune response
HCL2 is not toxic to host cells
ESAT-6 is one of the major secretory proteins of M.tb and plays a critical role in mycobacterial pathogenesis. In extracellular milieu, it modulates the host immune response and facilitates bacterial spread and dissemination among macrophages and dendritic cells [14, 15, 21–24]. Furthermore, a large body of literature suggests that effective protection against TB requires both Th1 and Th17 responses from host [3–6]. Role of mycobacterial secretory protein ESAT-6, a protein derived from the region of difference (RD-1), in mounting Th17 responses in the lung has been established earlier by us . The inability of the only known vaccine, BCG, to mount Th17 response can be attributed to the absence of region RD-1 that codes for ESAT-6 and its cognate secretion system. This raises the possibility that RD-1 substituted BCG could serve as a better vaccine. Indeed, immune responses induced by RD-1 recombinant BCG provide superior vaccine efficacy. However, RD-1 substitution in BCG makes the recombinant strain gain virulence, and thus is not suitable for vaccine implication [10, 25–27].
We aimed to identify a novel peptide that can incapacitate ESAT-6 and counter its debilitating functions on host system. In our effort to disrupt virulence, we chose to screen peptides from human origin so as to avoid unwanted immune response. The study presented here has demonstrated that HCL2, a peptide from human COX3 protein, strongly binds ESAT-6, disrupts ESAT-6:CFP10 association, and inhibits the growth of M.tb in axenic cultures and in macrophages and mice. This is the first example of a peptide disrupting a known protein-protein interaction. HCL2 is part of a seven-bundle helix of COX3 and homology-based modeling shows that it forms a helical structure that interacts with ESAT-6, possibly through hydrophobic interactions – a likely scenario as ESAT-6 itself forms a helix-turn-helix and interacts with the helical arm of CFP10 due to hydrophobic interactions (Additional file 4: Figure S4B).
HCL2 disrupted the strong heterodimeric interaction between ESAT-6 and CFP10 in vivo and led to significant reduction in extracellular and intracellular mycobacterial growth. Incapacitation of ESAT-6 by HCL2 could hinder the cell-to-cell spread, as also indicated by effects of HCL2 on intracellular mycobacterium. Therefore, HCL2 has the potential to inhibit M.tb spread and pathogenesis inside macrophages.
Interestingly, our electron microscopy data showed distinct degeneration of cell wall and changes in the cell morphology in presence of HCL2 peptide, both endogenous and exogenous. Likewise, mycobacteria expressing HCL2 formed a distinctly smoothened colony. To rule out the general cytotoxic nature of HCL2, its treatment of uninfected THP-1 cell lines and E. coli with HCL2 had no effect, suggesting that it is rather specific to M.tb (data not shown); in addition H37Rv/HCL2 infections were non toxic to mice alveolar lymphocytes and peritoneal macrophages.
One possibility is that HCL2 binds and disrupts the secretion system at a location on the bacterial cell surface that harbors the ESAT-6:CFP10 complex, leading to accumulation of toxic material inside the cells resulting in weak growth. This hypothesis is further strengthened by the fact that treatment of H37Rv with unrelated peptides had no effect on the growth. Notably, intracellular survival of the pathogen inside human macrophagial THP-1 cell line was also hindered by HCL2. Mycobacterial strain expressing HCL2 was cleared surprisingly fast from the cells and similar effects were observed when cells infected with wild type H37Rv were treated with HCL2 exogenously.
To establish the type of immune response raised by HCL2-expressing H37Rv (H37Rv/HCL2), BALB/c mice were infected with H37Rv/HCL2 and mycobacterial survival and immune response were studied. The HCL2 expressing strain was cleared in two weeks duration while H37Rv continued to grow exponentially showed the normal growth defect. H37Rv/HCL2 enhanced T cell, macrophage and dendritic cells proliferation and led to activation of CD4+ populations. The cytokine milieu in H37Rv/HCL2 showed significant up-regulation of IFN-γ, IL-17, IL-9, IL-12, TNF-α, IL-6 and IL-22. It is clear that H37Rv/HCL2 induces host protective immune responses. It was important to find out whether there was a potent enhancement in IL-17, IL6 and IL-22 cytokines, the key regulators of Th17 response, as it is widely believed that Th1 and Th17 responses play important roles in host protective immunity, unlike BCG that is unable to mount a Th17 response. Indeed, we observed that the recombinant strain mounts a strong Th1 and Th17 host protective response, we believe ultimately responsible for the accelerated clearance of this recombinant strain.
This is the first study demonstrating the ability of a novel peptide HCL2 to disrupt the ESAT-6:CFP10 heterodimeric complex and significantly affect growth of both extracellular and intracellular bacteria, as well as cellular morphology and colony texture on solid media. Concomitantly, in preclinical mouse model system, HCL2 has shown significant reduction in mycobacterial infection and strong protective immune response. This study was aimed as a proof-of-concept validation and long-term vaccine efficacy experiments are currently the focus of our laboratories.
We have demonstrated that disruption of ESAT-6:CFP10 attenuates virulence in M. tuberculosis rendering faster clearance in mice. Unlike BCG or ΔRD1, HCL2 recombinant M. tuberculosis retains better host protective immune responses. The present study lays the foundation for a possible BCG alternative and thus deserves attention and testing for eventual human application. Further studies, involving direct comparison with BCG, will throw more light on this possibility, while at the same time, separately; HCL2 offers a tantalizing template for the synthesis of anti-TB peptidomimetic molecules.
We thank Akash Saini for help in electron microscopy experiments and Prof. Belisle for the kind gift of pVV16 mycobacterial shuttle vector. The use of ICGEB TCAF bio-safety lab is gratefully acknowledged. This work was supported by internal grants from the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
- Global tuberculosis control: Annual Report on Global Tuberculosis Scenario by World Health Organization. 2011, [http://whqlibdoc.who.int/publications/2011/9789241564380_eng.pdf] Accessed 05 February 2012Google Scholar
- Kaufmann SH: Is the development of a new tuberculosis vaccine possible?. Nat Med. 2000, 6: 955-960.View ArticlePubMedGoogle Scholar
- Chatterjee S, Dwivedi VP, Singh Y, Siddiqui I, Sharma P, Van Kaer L, Chattopadhyay D, Das G: Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes protective T helper 17 cell responses in a toll-like receptor-2-dependent manner. PLoS Pathog. 2011, 7: e1002378-View ArticlePubMedPubMed CentralGoogle Scholar
- Chandra Rai R, Dwivedi VP, Chatterjee S, Raghava Prasad DV, Das G: Early secretory antigenic target-6 of Mycobacterium tuberculosis: enigmatic factor in pathogen-host interactions. Microbes Infect. 2012, 14: 1220-1226.View ArticlePubMedGoogle Scholar
- Hokey DA, Ginsberg A: The current state of tuberculosis vaccines. Hum Vaccin Immunother. 2013, 9: 48-47. PMID: 23792698; http://dx.doi.org/10.4161/hv.25427 View ArticleGoogle Scholar
- Bonah C: The 'experimental stable' of the BCG vaccine: safety, efficacy, proof, and standards, 1921–1933. Stud Hist Philos Biol Biomed Sci. 2005, 36: 696-721.View ArticlePubMedGoogle Scholar
- Zhang Y: The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005, 45: 529-564.View ArticlePubMedGoogle Scholar
- Yew WW, Leung CC: Antituberculosis drugs and hepatotoxicity. Respirology. 2006, 11: 699-707.View ArticlePubMedGoogle Scholar
- Alksne LE: Virulence as a target for antimicrobial chemotherapy. Expert Opin Investig Drugs. 2002, 11: 1149-1159.View ArticlePubMedGoogle Scholar
- Pym AS, Brodin P, Brosch R, Huerre M, Cole ST: Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol. 2002, 46: 709-712.View ArticlePubMedGoogle Scholar
- Renshaw PS, Panagiotidou P, Whelan A, Gordon SV, Hewinson RG, Williamson RA, Carr MD: Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterization of the structural properties of ESAT-6, CFP-10, and the ESAT-6:CFP-10 Complex. J Biol Chem. 2002, 277: 21598-21603.View ArticlePubMedGoogle Scholar
- Meher AK, Bal NC, Chary KV, Arora A: Mycobacterium tuberculosis H37Rv ESAT-6–CFP-10 complex formation confers thermodynamic and biochemical stability. FEBS J. 2006, 273: 1445-1462.View ArticlePubMedGoogle Scholar
- Lewis KN, Liao R, Guinn KM, Hickey MJ, Smith S, Behr MA, Sherman DR: Deletion of RD1 from Mycobacterium tuberculosis Mimics Bacille Calmette-Guerin Attenuation. J Infect Dis. 2003, 187: 117-123.View ArticlePubMedGoogle Scholar
- de Jonge MI, Pehau-Arnaudet G, Fretz MM, Romain F, Bottai D, Brodin P, Honoré N, Marchal G, Jiskoot W, England P, Cole ST, Brosch R: ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J Bacteriol. 2007, 189: 6028-6034.View ArticlePubMedPubMed CentralGoogle Scholar
- Volkman HEV, Clay H, Beery D, Chang JC, Sherman DR, Ramakrishnan L: Tuberculous granuloma formation is enhanced by a mycobacterium virulence determinant. PLoS Biol. 2004, 2: e367-View ArticlePubMedPubMed CentralGoogle Scholar
- Tharad M, Samuchiwal SK, Bhalla K, Ghosh A, Kumar K, Kumar S, Ranganathan A: A three-hybrid system to probe in vivo protein-protein interactions: application to the essential proteins of the RD1 complex of M. tuberculosis. PLoS One. 2011, 6: e27503-View ArticlePubMedPubMed CentralGoogle Scholar
- Kumar K, Tharad M, Ganapathy S, Ram G, Narayan A, Khan JA, Pratap R, Ghosh A, Samuchiwal SK, Kumar S, Bhalla K, Gupta D, Natarajan K, Singh Y, Ranganathan A: Phenylalanine-rich peptides potently bind ESAT-6, a virulence determinant of Mycobacterium tuberculosis, and concurrently affect the pathogen’s growth. PLoS One. 2009, 4: e7615-View ArticlePubMedPubMed CentralGoogle Scholar
- Kumar D, Nath L, Kamal MA, Varshney A, Jain A, Singh S, Rao KV: Genome wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell. 2010, 140: 731-743.View ArticlePubMedGoogle Scholar
- Tousif S, Singh Y, Prasad DV, Sharma P, Van Kaer L, Das G: T cells from programmed death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS One. 2011, 6: e19864-View ArticlePubMedPubMed CentralGoogle Scholar
- Lamichhane G, Raghunand TR, Morrison NE, Woolwine SC, Tyagi S, Kandavelou K, Bishai WR: Deletion of a Mycobacterium tuberculosis proteasomal ATPase homologue gene produces a slow-growing strain that persists in host tissues. J Infect Dis. 2006, 9: 1233-1240.View ArticleGoogle Scholar
- Wang X, Barnes PF, Dobos-Elder KM, Townsend JC, Chung YT, Shams H, Weis SE, Samten B: ESAT-6 inhibits production of IFN-γ by Mycobacterium tuberculosis-responsive human T cells. J Immunol. 2009, 182: 3668-3677.View ArticlePubMedGoogle Scholar
- Guo S, Xue R, Li Y, Wang SM, Ren L, Xu JJ: The CFP10/ESAT-6 complex of Mycobacterium tuberculosis may function as a regulator of macrophage cell death at different stages of tuberculosis infection. Med Hypotheses. 2012, 78: 389-392.View ArticlePubMedGoogle Scholar
- Derrick SC, Morris SL: The ESAT-6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression. Cell Microbiol. 2007, 9: 1547-1555.View ArticlePubMedGoogle Scholar
- Samten B, Wang X, Barnes PF: Mycobacterium tuberculosis ESX-1 system-secreted protein ESAT-6 but not CFP10 inhibits human T-cell immune responses. Tuberculosis. 2009, 89: S74-S76.View ArticlePubMedGoogle Scholar
- Mahairas GG, Sabo JJ, Hickey MJ, Singh DC, Stover CK: Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 1996, 178: 1274-1282.PubMedPubMed CentralGoogle Scholar
- Brodin P, Rosenkrands I, Andersen P, Cole ST, Brosch R: ESAT-6 proteins: protective antigens and virulence factors?. Trends Microbiol. 2004, 12: 500-508.View ArticlePubMedGoogle Scholar
- Ganguly N, Siddiqui I, Sharma P: Role of M. tuberculosis RD-1 region encoded secretory proteins in protective response and virulence. Tuberculosis (Edinb). 2008, 88: 510-517.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/14/355/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.